PFAS Forever Chemicals: Understanding Their Impact on Thyroid Function and Immunity

Overview

Per- and polyfluoroalkyl substances (PFAS), universally classified as persistent organic pollutants or "forever chemicals," represent a profound paradigm shift in molecular toxicology and endocrine disruption. Characterised by an exceptionally robust carbon-fluorine bond—one of the strongest in organic chemistry—these synthetic compounds resist thermal, chemical, and biological degradation, ensuring bioaccumulation across trophic levels and a remarkably protracted half-life within the human serum. Epidemiological and toxicological data catalogued across major repositories, including PubMed and comprehensive assessments by UK environmental and health agencies, indicate that contemporary human exposure is ubiquitous. Diet, potable water, and consumer matrices serve as primary vectors, driving chronic, low-dose systemic intoxication that fundamentally subverts human physiological homeostasis, with the endocrine and immune networks acting as primary nodes of toxicity.

At the physiological core of this disruption is the profound structural mimicry that specific PFAS homologues—most notably perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS)—exhibit toward endogenous substrates. Within the endocrine architecture, these xenobiotics operate as potent multi-modal disruptors of the Hypothalamic-Pituitary-Thyroid (HPT) axis. Mechanistic investigations demonstrate that PFAS molecules competitively bind to thyroid hormone transport proteins, such as transthyretin and thyroxine-binding globulin, thereby displacing endogenous thyroxine ($T4$) and triiodothyronine ($T3$). This displacement artificially inflates free hormone levels in the short term, triggering feedback loops that downregulate thyroid-stimulating hormone (TSH) synthesis, ultimately resulting in tissue-level hypothyroidism despite systemic concentrations appearing deceptively normal within standard clinical assay ranges. Furthermore, peer-reviewed literature indexed in The Lancet and related high-impact journals reveals that PFAS actively perturb hepatic uridine diphosphate-glucuronosyltransferases (UGTs), accelerating the metabolic clearance and biliary excretion of active thyroid hormones.

Concurrently, the immunological consequences of chronic PFAS exposure are profound and multifaceted. Immunotoxicity manifests primarily through the suppression of humoral and cell-mediated adaptive responses. Epidemiological cohorts exposed to high environmental burdens of PFAS demonstrate blunted antibody titers following vaccination, alongside altered cytokine signalling cascades. At the cellular level, these amphiphilic compounds intercalate into lipid bilayers, altering membrane fluidity and intracellular calcium signaling within lymphocytes and antigen-presenting cells. At INNERSTANDIN, our synthesis of current toxicological paradigms underscores that this dual-action pathology—simultaneously subverting metabolic set-points via the HPT axis and compromising immunosurveillance—creates a systemic vulnerability. The convergence of thyroid dysregulation and immunotoxicity exposes populations to heightened risks of metabolic syndrome, oncogenesis, and chronic inflammatory states, establishing PFAS contamination as one of the most critical, unaddressed chemical threats to modern human biology.

The Biology — How It Works

Per- and polyfluoroalkyl substances (PFAS), colloquially termed 'forever chemicals' due to the exceptionally resilient carbon-fluorine bond, exert profound disruptions across human endocrine and immune networks. At a cellular level, the biological threat of PFAS—predominantly long-chain congeners such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS)—stems from their structural mimicry of endogenous molecules. Because of their amphiphilic properties, these persistent organic pollutants readily cross biological membranes, bioaccumulating within serum proteins, hepatic tissue, and secondary lymphoid organs.

The primary axis of endocrine disruption involves the hypothalamic-pituitary-thyroid (HPT) axis. Toxicological evaluations indexed in PubMed demonstrate that PFAS compounds possess a high binding affinity for thyroid hormone transport proteins, specifically thyroxine-binding globulin (TBG) and transthyretin (TTR). By competitively displacing endogenous thyroxine ($T4$) and triiodothyronine ($T3$) from these carrier proteins, PFAS artificially inflates free hormone levels in the systemic circulation. This transient surge triggers a negative feedback loop at the level of the hypothalamus and anterior pituitary, artificially downregulating thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH). Consequently, clinical and epidemiological cohorts—including comprehensive biomonitoring data from the UK population—frequently correlate chronic PFAS exposure with aberrant subclinical thyroid profiles, blunted metabolic rates, and disrupted cellular thermogenesis. Furthermore, in vitro studies reveal that PFAS inhibit iodothyronine deiodinases (the enzymes responsible for converting peripheral $T4$ into the biologically active $T3$), compounding intracellular hypothyroidism despite seemingly normal serum markers.

Simultaneously, the immunotoxicological mechanisms of PFAS dismantle host defense architecture. Landmark studies published in The Lancet and specialized immunological journals establish that developmental and chronic exposure to these synthetic compounds suppresses humoral immune responses, notably diminishing vaccine antibody titre production in paediatric and adult cohorts. Mechanistically, PFAS act as peroxisome proliferator-activated receptor (PPAR) agonists, particularly targeting PPAR-$\alpha$ and PPAR-$\gamma$ pathways within lymphocytes and macrophages. This agonism alters lipid homeostasis within the cell membrane, impairing signal transduction cascades essential for T-cell proliferation and B-cell differentiation. Furthermore, transcriptomic analyses indicate that PFAS downregulate the expression of critical chemokines and pro-inflammatory cytokines required for effective pathogen clearance, while simultaneously inducing apoptosis in thymocytes.

Here at INNERSTANDIN, we emphasize that the insidious nature of PFAS lies in this multi-system cross-talk: the disruption of thyroid hormones directly impairs immune cell maturation and metabolic readiness, creating a compounded state of systemic vulnerability. As environmental accumulation persists across the British Isles, unravelling these precise molecular pathways is critical for defining true toxicological thresholds and safeguarding human physiological integrity.

Mechanisms at the Cellular Level

At the microscopic interface of human physiology and environmental toxicology, per- and polyfluoroalkyl substances (PFAS)—ubiquitously characterised as 'forever chemicals' due to their extraordinarily stable carbon-fluorine bonds—exert insidious disruptions at the cellular and molecular tiers. Within UK populations, biomonitoring initiatives consistently reveal systemic bioaccumulation of long-chain and short-chain congeners, notably perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA). These xenobiotic molecules operate as potent endocrine-disrupting chemicals (EDCs), structurally mimicking endogenous substrates to hijack critical signaling cascades, downregulate receptor expression, and fundamentally alter cellular homeostasis within both the thyroid axis and the immune apparatus.

To understand the disruption of thyroid homeostasis, one must examine the basolateral membrane of thyrocytes, where PFAS structurally mimic thyroid hormones, specifically thyroxine ($\text{T}4$) and triiodothyronine ($\text{T}3$). Due to their lipophilic-hydrophobic amphiphilic properties, PFAS molecules competitively bind to circulating transport proteins, predominantly transthyretin (TTR) and serum albumin. Peer-reviewed toxicological data indexed in PubMed demonstrate that congeners like PFOS exhibit a higher binding affinity for TTR than endogenous $\text{T}4$. This competitive displacement forces an immediate surge in free, unbound thyroid hormones in the serum, triggering a negative feedback loop at the hypothalamus-pituitary-thyroid (HPT) axis. Paradoxically, chronic cellular exposure results in hepatic upregulation of uridine diphosphate-glucuronosyltransferases (UGTs)—enzymes driven by the activation of constitutive androstane receptors (CAR) and pregnane X receptors (PXR)—which subsequently accelerate the clearance and biliary excretion of $\text{T}4$. Consequently, peripheral tissues experience a state of functional hypothyroidism despite anomalous circulating profiles, impairing oxidative phosphorylation, mitochondrial respiration, and basal metabolic regulation at the cellular level.

Simultaneously, the immunotoxicological mechanisms of PFAS unfold via profound modulation of both innate and adaptive immune effector cells. PFAS molecules readily cross phospholipid bilayers, accumulating intracellularly where they engage peroxisome proliferator-activated receptors (PPARs)—specifically PPAR-$\alpha$ and PPAR-$\gamma$—along with nuclear factor kappa B ($\text{NF-}\kappa\text{B}$) pathways. In lymphocytes, macrophages, and dendritic cells, this receptor-mediated activation alters transcriptional regulation, culminating in suppressed antibody synthesis and blunted cytokine production. Landmark epidemiological and toxicological studies, including cohorts evaluated in European environmental health reviews, highlight a direct correlation between elevated serum PFAS concentrations and diminished vaccine antibody titres in paediatric and adult populations across the UK. Furthermore, PFAS exposure induces apoptosis in thymocytes and disrupts the clonal expansion of B-cells by impairing calcium influx necessary for downstream antigen-receptor signaling. By decoupling regular macrophage phagocytosis and subverting cytokine networks, these persistent pollutants engender an immunosuppressive cellular microenvironment, heightening host susceptibility to infectious pathogens and compromising immunosurveillance against neoplastic transformation. Through these intertwined endocrinological and immunological pathways, documented extensively across contemporary biomedical literature, INNERSTANDIN maps the precise molecular signatures by which industrial fluorochemicals systematically erode human biological resilience.

Environmental Threats and Biological Disruptors

Per- and polyfluoroalkyl substances (PFAS), colloquially designated as "forever chemicals," represent a profound paradigm shift in environmental toxicology. Characterised by an exceptionally robust carbon-fluorine (C-F) bond—one of the most stable covalent linkages in organic chemistry—these xenobiotic compounds exhibit extreme persistence against thermal, chemical, and biological degradation. Bioaccumulation of long-chain variants such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) within aquatic and terrestrial ecosystems has precipitated ubiquitous human exposure. As documented in biomonitoring surveys by UK health authorities, including the UK Health Security Agency (UKHSA), these molecules are detectable in the serum of a vast majority of the population, entering systemic circulation primarily via contaminated potable water, dietary ingestion, and bio-amplification across trophic webs.

At the physiological level, PFAS function as potent endocrine-disrupting chemicals (EDCs), interfering with homeostatic feedback loops by mimicking, blocking, or altering the synthesis, transport, and metabolism of endogenous hormones. The structural analogues of certain PFAS allow them to competitively bind to transport proteins, most notably serum albumin and transthyretin, thereby displacing essential physiological ligands and dramatically altering thyroid hormone bioavailability. Peer-reviewed toxicological data indexed in PubMed demonstrate that chronic low-dose exposure disrupts the hypothalamic-pituitary-thyroid (HPT) axis. Specifically, PFAS compounds interfere with the cellular uptake of iodide via the sodium-iodide symporter (NIS) in the thyroid follicular cells, impairing thyroid peroxidase (TPO) enzymatic activity and subsequently depressing the synthesis of thyroxine ($\text{T}4$) and triiodothyronine ($\text{T}3$). This chemical interference frequently manifests as subclinical hypothyroidism, marked by elevated thyroid-stimulating hormone (TSH) levels and blunted metabolic regulation.

Concurrently, the immunological consequences of PFAS exposure are deeply concerning, particularly regarding adaptive immunity. Landmark epidemiological and toxicological studies published in The Lancet Planetary Health and associated immunology journals reveal a striking inverse correlation between serum PFAS concentrations and vaccine antibody titres in paediatric and adult cohorts. Mechanistically, PFAS exert immunotoxic effects by targeting lymphocyte proliferation, altering cytokine signalling cascades, and disrupting macrophage function. These anthropogenic agents modulate peroxisome proliferator-activated receptors (PPAR-alpha and PPAR-gamma), which play critical regulatory roles in both lipid metabolism and inflammatory pathways. By aberrantly activating these nuclear receptors, PFAS induce chronic, low-grade systemic inflammation while simultaneously dampening the clonal expansion of B-cells and T-cells during antigenic challenge.

For scholars, clinicians, and health-conscious individuals utilising INNERSTANDIN to dissect the complexities of molecular toxicology, the narrative surrounding PFAS transcends simple environmental pollution. It highlights a systemic biological crisis where persistent industrial agents dismantle human physiological resilience at the molecular level, compromising both metabolic homeostasis through endocrine disruption and immune competence via profound immunotoxicity.

The Cascade: From Exposure to Disease

To truly comprehend the toxicological footprint of per- and polyfluoroalkyl substances (PFAS), one must trace the pathophysiological pathway from environmental ingestion to wholesale systemic collapse. At INNERSTANDIN, our commitment is to decode these complex molecular trajectories. The human bioaccumulation cascade begins with the exceptional persistence of the carbon-fluorine bond, one of the strongest in organic chemistry. Upon entering the systemic circulation—predominantly via contaminated municipal water supplies or dietary vectors across the UK—long-chain and short-chain PFAS homologues exhibit a high affinity for serum proteins, bypassing standard hepatic clearance and evading renal excretion.

Once internalised, these xenobiotics function as potent endocrine-disrupting chemicals (EDCs), specifically targeting the hypothalamic-pituitary-thyroid (HPT) axis. Toxicogenomic data published in peer-reviewed literature, including repositories indexed in PubMed, demonstrate that compounds such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) act as competitive antagonists and partial agonists at thyroxine-binding globulin (TBG) binding sites. By structurally mimicking endogenous thyroxine ($\text{T}4$) and triiodothyronine ($\text{T}3$), PFAS displace these vital hormones into the free serum fraction, triggering a false-positive feedback loop at the level of the anterior pituitary. This misregulation inhibits thyroid-stimulating hormone (TSH) synthesis while paradoxically accelerating peripheral hormone catabolism through the upregulation of hepatic uridine diphosphate-glucuronosyltransferases (UGTs). The net clinical consequence is subclinical or overt hypothyroidism, characterised by diminished cellular metabolism, aberrant neurodevelopmental signalling, and impaired lipid homeostasis.

Simultaneously, the immunological cascade unfolds in parallel, driven by the immunotoxicological properties of legacy and novel PFAS formulations. Epidemiological and in vitro toxicological assays published in the Lancet and associated immunological journals reveal that PFAS molecules directly accumulate within secondary lymphoid organs. Here, they exert profound immunomodulatory effects on both innate and adaptive arms of the immune system. Perfluorinated compounds impair macrophage phagocytosis, disrupt dendritic cell maturation, and suppress lymphocyte proliferation. Mechanistically, this occurs via the activation of peroxisome proliferator-activated receptors (PPAR-alpha and PPAR-gamma) and the perturbation of nuclear factor kappa B ($\text{NF-}\kappa\text{B}$) signalling pathways.

The convergence of HPT axis disruption and cellular immunosuppression creates a synergistic pathological state. Thyroid hormones are fundamentally required for optimal thymic function and the maturation of T-lymphocytes; thus, PFAS-induced thyroid disruption inherently compromises immune surveillance. Furthermore, population-based studies tracking UK cohorts indicate that heightened systemic PFAS burdens attenuate antibody responses to standard vaccinations and elevate susceptibility to autoimmune thyroiditis, such as Hashimoto's disease. By systematically dismantling the delicate feedback loops of the endocrine system while concurrently blunting the efficacy of the adaptive immune architecture, PFAS chemicals engineer a multi-systemic cascade that transitions the human organism from chronic low-dose exposure to overt, irreversible chronic disease states.

What the Mainstream Narrative Omits

While public health advisories and mainstream regulatory frameworks frequently reduce the threat of per- and polyfluoroalkyl substances (PFAS) to rudimentary discussions of bioaccumulation and gross oncogenic risk, they systematically omit the nuanced, low-dose molecular endocrinology that underpins systemic metabolic and immunological dysregulation. Standard epidemiological discourse often frames PFAS exposure as a passive, long-term toxicological burden. However, a rigorous evaluation of toxicogenomic data reveals an active, receptor-mediated disruption of homeostatic axes that standard regulatory models—often reliant on archaic, linear threshold assumptions—fail to capture.

At the cellular level, the mainstream narrative glosses over the structural mimicry that allows long-chain and emerging short-chain PFAS homologues to bypass physiological checkpoints. PFAS molecules do not merely float inertly within serum albumin; they function as potent xenobiotic disruptors capable of binding to key nuclear receptors, most notably the peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma) and the constitutive androstane receptor (CAR). By constitutively activating these pathways, PFAS alter lipid metabolism, upregulate oxidative stress pathways in hepatocytes, and fundamentally distort the signaling milieu required for euthyroid balance.

Crucially, standard toxicology reports largely ignore the multi-generational epigenetic reprogramming induced by gestational and lactational PFAS transfer. Research indexed in databases such as PubMed demonstrates that developmental exposure leads to aberrant DNA methylation patterns in promoter regions regulating thyroid-stimulating hormone (TSH) receptor expression and deiodinase enzymes (specifically D1 and D2), which catalyze the peripheral conversion of thyroxine ($\text{T}4$) to the active triiodothyronine ($\text{T}3$) form. This epigenetic footprint means that the physiological deficit extends far beyond the duration of active serum clearance, predisposing the offspring to subclinical hypothyroidism and blunted metabolic plasticity well into adulthood.

Furthermore, the immunological narrative promoted by conventional agencies frequently isolates immune suppression from endocrine disruption, treating them as disparate endpoints. Biological science demands an integrated view. PFAS-induced alterations in thyroid hormone availability directly compromise thymic involution, lymphocyte maturation, and macrophage phagocytic efficiency. Thyroid hormones are essential regulators of innate and adaptive immune cell proliferation; when circulating free $\text{T}_3$ is competitively displaced from nuclear receptors by fluorinated compounds, the downstream consequence is a compromised mucosal barrier and a suppressed antibody response—a mechanism only recently highlighted in European Food Safety Authority (EFSA) re-evaluations, yet still absent from mainstream clinical awareness in the UK.

By failing to account for toxicological synergism—the concurrent exposure to complex mixtures of legacy compounds like PFOS and PFOA alongside replacement variants like GenX—mainstream frameworks vastly underestimate the true biological footprint. At INNERSTANDIN, we emphasize that true mitigation requires moving beyond outdated single-chemical paradigms to confront the multi-systemic, receptor-level reality of persistent endocrine disruption.

The UK Context

Within the United Kingdom, the bioaccumulation of per- and polyfluoroalkyl substances (PFAS) represents an escalating public health crisis, with biomonitoring data from the UK Health Security Agency (UKHSA) and independent academic cohorts revealing widespread systemic exposure across the British population. British watersheds, agricultural soils, and urban centres exhibit persistent contamination profiles, primarily driven by historical industrial manufacturing, aqueous film-forming foams (AFFF) utilised at fire-training facilities, and the pervasive import of consumer goods treated with fluorinated compounds. As a premier biological education platform, INNERSTANDIN rigorously examines how these synthetic xenobiotics infiltrate British biological systems, focusing specifically on their disruption of the hypothalamic-pituitary-thyroid (HPT) axis and subsequent immunological dysregulation.

Mechanistically, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)—prominent congeners historically prevalent in UK industrial applications—exhibit striking structural analogues to endogenous thyroxine ($T4$) and triiodothyronine ($T3$). Peer-reviewed toxicology literature indexed in PubMed demonstrates that these persistent organic pollutants competitively bind to human serum transport proteins, notably transthyretin (TTR) and thyroid hormone-binding globulin (TBG). By displacing physiological thyroid hormones from their carrier proteins, PFAS artificially elevates free hormone fractions in the systemic circulation, triggering a negative feedback loop that suppresses thyroid-stimulating hormone (TSH) synthesis within the anterior pituitary. Furthermore, toxicogenomic assays published in The Lancet Planetary Health underscore that PFAS compounds upregulate hepatic uridine diphosphate-glucuronosyltransferases (UGTs), accelerating the phase II metabolic clearance and biliary excretion of circulating thyroid hormones. This dual action precipitates a state of functional hypothyroidism at the cellular level, impairing basal metabolic rate, neurodevelopmental homeostasis, and mitochondrial respiration across British cohorts.

Simultaneously, the immunotoxicological footprint of chronic PFAS exposure within the UK population compromises host defence mechanisms. Epidemiological tracking from birth-cohort studies reveals inverse correlations between elevated serum PFAS burdens and diminished antibody titre responses to routine paediatric vaccinations, such as tetanus and diphtheria. At the cellular level, perfluorinated alkyl acids modulate peroxisome proliferator-activated receptors (PPAR-alpha and PPAR-gamma), which are abundantly expressed on the membranes of lymphocytes, macrophages, and dendritic cells. Activation of these nuclear receptors alters cytokine signalling cascades, suppressing cell-mediated immunity while predisposing biological systems to chronic, low-grade systemic inflammation. For researchers navigating the intersection of environmental toxicology and endocrinology, INNERSTANDIN emphasises that the persistence of these anthropogenic agents demands an urgent re-evaluation of UK drinking water safety thresholds and regulatory frameworks to mitigate their multi-systemic pathological cascade.

Protective Measures and Recovery Protocols

Mitigating the pervasive bioaccumulation of per- and polyfluoroalkyl substances (PFAS) necessitates a multi-tiered biochemical strategy designed to interrupt enterohepatic recirculation and enhance renal excretion pathways. Because perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)—the legacy compounds most extensively studied in UK water systems and human serum biomonitoring—exhibit terminal elimination half-lives spanning years to decades, passive clearance is insufficient to protect the thyroperoxidase (TPO) enzyme and systemic immune architecture. At INNERSTANDIN, our analysis of toxicokinetic data published in The Lancet Planetary Health and peer-reviewed PubMed repositories demonstrates that targeted intervention must focus on downregulating reabsorption dynamics in the proximal renal tubules and gut.

A cornerstone of clinical recovery protocols involves the interruption of the enterohepatic loop. Due to their amphiphilic properties, PFAS molecules undergo significant biliary secretion followed by active reabsorption in the ileum. Pharmacokinetic modelling reveals that non-absorbable sequestrants, particularly pharmaceutical-grade anion-exchange resins such as cholestyramine, can bind luminal PFAS anions within the gastrointestinal tract, effectively increasing faecal excretion rates. Clinical trials cited in environmental toxicology literature confirm that such ion-trapping mechanisms can accelerate the clearance of specific long-chain PFAS, mitigating their antagonistic binding affinity for thyroid hormone transport proteins like transthyretin (TTR) and thyroxine-binding globulin (TBG).

Simultaneously, supporting phase II hepatic biotransformation and conjugation pathways is critical, even though PFAS are notoriously resistant to direct enzymatic degradation. Upregulating phase II conjugation (glucuronidation via UDP-glucuronosyltransferases and sulfation via sulfotransferases) facilitates the polar conversion of endogenous thyroid hormones (T4 to rT3 or T3 excretion) and reduces secondary oxidative stress caused by PFAS-induced mitochondrial uncoupling in thyrocytes and lymphocytes. Furthermore, maintaining optimal selenium status is vital; selenium acts as an essential cofactor for iodothyronine deiodinases, counteracting the inhibitory cascades triggered by perfluorinated exposures on peripheral thyroid hormone conversion.

At the systemic level, reducing the inflammatory burden and immune dysregulation caused by PFAS-induced nuclear receptor activation (such as PPAR-alpha and PPAR-gamma modulation) requires meticulous dietary and supplemental immunomodulation. Clinical interventions often incorporate targeted antioxidant therapies—specifically N-acetylcysteine (NAC) and glutathione precursors—to restore intracellular redox balance within thymic and splenic compartments, where PFAS-induced apoptosis of T-lymphocytes compromises adaptive immunity. Additionally, clinical phlebotomy (donating blood or plasma) has emerged in recent epidemiological studies as an empirically validated mechanical intervention. Because PFAS bind avidly to serum albumin rather than adipose tissue, serial blood donation significantly reduces circulating serum concentrations, directly lowering the internal dose bombarding the hypothalamic-pituitary-thyroid (HPT) axis.

Finally, primary prevention remains paramount within the UK regulatory context. Mitigating ongoing exposure requires point-of-use granular activated carbon (GAC) and high-pressure reverse osmosis filtration systems capable of reducing sub-nanogram per litre concentrations in drinking water. By synergising environmental exposure elimination with biochemical clearance protocols, physiological resilience against endocrine disruption can be systematically restored.

Summary: Key Takeaways

Accumulating toxicological evidence from peer-reviewed literature indexed in PubMed and prominent epidemiological surveys highlighted by UK regulatory bodies demonstrate that per- and polyfluoroalkyl substances (PFAS) function as potent endocrine-disrupting chemicals (EDCs), fundamentally compromising human homeostasis. Mechanistically, these synthetic aliphatic compounds—characterised by recalcitrant carbon-fluorine bonds—exhibit structural mimicry to endogenous thyroxine ($\text{T}4$) and triiodothyronine ($\text{T}3$), competitively binding to thyroxine-binding globulin (TBG) and disrupting hypothalamic-pituitary-thyroid (HPT) axis feedback loops. This disruption leads to insidious aberrations in circulating thyroid hormone bioavailability, precipitating subclinical hypothyroidism and downstream metabolic dysregulation. Concurrently, immunotoxicological evaluations published in journals such as The Lancet reveal that chronic PFAS bioaccumulation suppresses humoral and cell-mediated immune responses, diminishing vaccine efficacy and elevating susceptibility to infectious pathologies through the targeted downregulation of cytokine signalling and lymphocyte proliferation. At INNERSTANDIN, our synthesis of these molecular pathways underscores an urgent biomedical imperative: mitigating environmental PFAS exposure is critical to halting systemic endocrine suppression and immune exhaustion across the population.